[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653907":3},{"organization":4,"outcomesModule":7,"designInfo":32,"detailedDescription":31,"studyPopulation":31,"armGroups":38,"interventions":50,"overallOfficials":31,"centralContacts":56,"locations":31,"responsibleParty":62,"collaborators":31,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":31,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":31,"enrollmentInfo":75,"targetDuration":31,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":31,"overallStatus":84,"whyStopped":31,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":31},{"fullName":5,"class":6},"Zhujiang Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":31},[9,13],{"measure":10,"description":11,"timeFrame":12},"Incidence of Dose-Limiting Toxicities (DLTs)","Number of participants with MSC-Exos-related DLTs, defined as grade ≥3 local peritoneal reactions (abdominal pain \u002F signs of peritonitis) or systemic allergic reactions assessed by CTCAE v5.0. Local reactions will be objectively supported by peritoneal effluent white blood cell count and polymorphonuclear (PMN) cell percentage.","Within 72 hours post-administration",{"measure":14,"description":15,"timeFrame":16},"Incidence of Serious Adverse Events (SAEs)","Number of participants experiencing SAEs during the entire study period. Safety monitoring includes serial assessments of complete blood count, C-reactive protein (CRP), and liver\u002Fkidney function tests (ALT, AST, creatinine, BUN).","Up to 4 weeks post-administration",[18,22,25,28],{"measure":19,"description":20,"timeFrame":21},"Change in 4-hour Ultrafiltration Volume","Change from baseline to Week 4 in 4-hour ultrafiltration volume during modified peritoneal equilibration test (PET).","Baseline and Week 4",{"measure":23,"description":24,"timeFrame":21},"Change in 4-hour D\u002FPcr Ratio","Change from baseline to Week 4 in 4-hour dialysate-to-plasma creatinine (D\u002FPcr) ratio during modified PET.",{"measure":26,"description":27,"timeFrame":21},"Change in 1-hour Sodium Dip","Change from baseline to Week 4 in 1-hour sodium dip (absolute decrease in serum sodium) during modified PET.",{"measure":29,"description":30,"timeFrame":21},"Change in Sodium Sieve","Change from baseline to Week 4 in sodium sieve, calculated as the ratio of dialysate sodium at 1 hour to baseline plasma sodium during modified PET.",null,{"allocation":33,"interventionModel":34,"interventionModelDescription":31,"primaryPurpose":35,"observationalModel":31,"timePerspective":31,"maskingInfo":36},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":37,"maskingDescription":31,"whoMasked":31},"NONE",[39,44,47],{"label":40,"type":41,"description":31,"interventionNames":42},"Dose Level 1 (5×10⁹ particles)","EXPERIMENTAL",[43],"Biological: MSC-Exos",{"label":45,"type":41,"description":31,"interventionNames":46},"Dose Level 2 (2.5×10¹⁰ particles)",[43],{"label":48,"type":41,"description":31,"interventionNames":49},"Dose Level 3 (1×10¹¹ particles)",[43],[51],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":31},"BIOLOGICAL","MSC-Exos","MSC-Exos will be added to 2 L of 1.5% glucose peritoneal dialysis fluid, which will be administered via intraperitoneal infusion and retained for 8 hours.",[40,45,48],[57],{"name":58,"role":59,"phone":60,"phoneExt":31,"email":61},"Xun T Chief physicians","CONTACT","+86 20 6278 2305","1847672118@qq.com",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Xun Tang","Chief physicians","100653907","phase-1-the-therapeutic-potential-of-mesenchymal-stem-cell-derived-exosomes-in-peritoneal-dysfunction-100653907",false,"NCT07791667","The Therapeutic Potential of Mesenchymal Stem Cell-derived Exosomes in Peritoneal Dysfunction","A Phase I, Single-center, Open-label Study to Evaluate the Safety, Tolerability, and Dose-finding of Mesenchymal Stem Cell-derived Exosomes in the Treatment of Peritoneal Dialysis-related Peritoneal Dysfunction","Inclusion Criteria:\n\n1. Patients who have been on continuous peritoneal dialysis for more than 1 year.\n2. Age ≥ 18 years.\n3. Patients meeting at least one of the following criteria for peritoneal ultrafiltration insufficiency:\n\n   * Standard PET-confirmed ultrafiltration failure: 4-hour ultrafiltration volume \\\u003C 400 mL using 4.25% glucose dialysate, or \\\u003C 100 mL using 2.5% glucose dialysate; ② 1-hour sodium dip \\\u003C 5 mmol\u002FL and\u002For 1-hour sodium sieve ratio ≤ 0.03 using 4.25% glucose dialysate; ③ Inability to maintain fluid balance, as evidenced by persistent edema\u002Fheart failure symptoms, NT-proBNP \\>11215.2 ng\u002FL, or bioimpedance spectroscopy-assessed overhydration (OH) \\>2 L (after excluding non-peritoneal causes).\n\nExclusion Criteria:\n\n1. Patients with acute renal failure or chronic renal failure who can be temporarily weaned from dialysis.\n2. Patients with malignant tumors, active infections, or severe malnutrition.\n3. Patients with severe hepatic failure or cirrhosis.\n4. Patients with severe cardiovascular disease, severe heart failure (NYHA Class IV or higher), or active systemic diseases.\n5. Patients with peritonitis within the past 3 months or currently experiencing peritonitis.\n6. Patients with encapsulating peritoneal sclerosis (EPS).\n7. Patients with peritoneal dialysis catheter dysfunction.\n8. Planned or ongoing pregnancy.\n9. Simultaneous participation in another interventional clinical trial or drug study.","ALL","18 Years",{"count":76,"type":77},12,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","The goal of this clinical trial is to learn if a single intraperitoneal infusion of mesenchymal stem cell-derived exosomes (MSC-Exos) is safe and tolerable in adults with peritoneal dialysis-related peritoneal failure. It will also explore whether MSC-Exos might improve how well the peritoneum works (ultrafiltration and solute transfer).\n\nThe main questions it aims to answer are:\n\nWhat is the highest single dose of MSC-Exos that can be given safely without causing unacceptable side effects? (This helps find the maximum tolerated dose and the dose to use in future phase II studies.)\n\nWhat medical problems (adverse events) do participants experience after receiving MSC-Exos?\n\nDoes MSC-Exos show any early signs of improving ultrafiltration volume and solute transport across the peritoneum?\n\nResearchers will test increasing doses of MSC-Exos in small groups of participants. Each participant will receive one dose of MSC-Exos added to their usual 1.5% glucose dialysis solution (2 litres), which is then left in the abdominal cavity for 8 hours. The study does not use a placebo; instead, different dose levels are tested one after another to find the safest and most promising dose.\n\nParticipants will:\n\nReceive a single intraperitoneal infusion of MSC-Exos through their dialysis catheter\n\nBe monitored closely before the infusion；\n\nAttend follow-up visits at 24 hours, 72 hours, 2 weeks, and 4 weeks after the dose;\n\nHave blood and peritoneal effluent samples taken at each visit to check for safety ;\n\nHave their ultrafiltration volume and solute transport ability measured at baseline and 4 weeks after the dose to see if any changes occur.\n\nAll participants will be closely observed for any side effects. The results will help decide whether further studies are warranted.",[83],"Peritoneal Dysfunction","NOT_YET_RECRUITING","2026-08-27",{"date":87,"type":88},"2026-08-28","ACTUAL",{"date":90,"type":77},"2026-08",{"date":92,"type":77},"2027-08",{"name":5,"class":6}]